📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vineet Laboratories Extends Rights Issue Closing Date to January 30, 2026
Vineet Laboratories Limited has announced an extension of its ongoing Rights Issue timeline following a committee meeting on January 13, 2026. The last date for On-Market Renunciation has been moved to January 27, 2026, while the overall Issue Closing Date is now January 30, 2026. This extension is intended to provide more time for investors to participate in the fundraising process. Following the closure, the basis of allotment and listing of shares are scheduled for February 2 and February 3, 2026, respectively.
Key Highlights
Last date for On-Market Renunciation of Rights Entitlements extended to January 27, 2026
Rights Issue closing date officially extended to January 30, 2026
Basis of Allotment and Allotment of Shares scheduled for February 2, 2026
Listing of new Equity Shares on BSE and NSE expected by February 3, 2026
💼 Action for Investors
Investors holding Rights Entitlements (REs) should ensure they either subscribe to the issue or sell their REs on the market by January 27 to avoid total value loss. Monitor the share price relative to the rights price to determine if subscription is financially viable.
Shyam Metalics Dec 2025: Stainless Steel Vol Up 19% YoY, Speciality Alloys Up 50% YoY
Shyam Metalics reported a robust performance in its value-added segments for December 2025, with Stainless Steel volumes growing 19.07% YoY and realizations increasing by 18.18%. Speciality Alloys saw a significant volume surge of 50.05% YoY, while the newly commissioned CR Coil/Sheets plant led to a massive 835.77% YoY volume jump. However, the Carbon Steel segment faced headwinds with volumes and realizations declining by 8.03% and 4.40% YoY, respectively. Overall, the shift toward high-margin products like Stainless Steel and Speciality Alloys remains a key growth driver for the company.
Key Highlights
Stainless Steel volumes rose 19.07% YoY to 9,393 MT with realizations up 18.18% to Rs. 1,44,988/MT.
Speciality Alloys volumes surged 50.05% YoY to 21,759 MT, maintaining strong growth momentum.
CR Coil/Sheets volumes jumped 835.77% YoY to 18,078 MT following the Jamuria plant commissioning in Nov 2024.
Carbon Steel volumes declined 8.03% YoY to 1,45,615 MT with a 4.40% drop in average realizations.
Sponge Iron volumes grew 19.52% YoY to 88,808 MT, although realizations softened by 7.98% YoY.
💼 Action for Investors
Investors should view the strong growth in high-margin Stainless Steel and Speciality Alloys as a positive sign of product mix optimization. While Carbon Steel realizations are under pressure, the rapid ramp-up of new capacities in CR Coils and Pig Iron provides a significant volume cushion.
Shyam Metalics Subsidiary RIL Commences 0.45 MTPA Blast Furnace Operations
Shyam Metalics and Energy Limited has announced that its step-down subsidiary, Ramsarup Industries Limited (RIL), has commenced commercial production at its new Modern Blast Furnace and Linear Sinter Plant as of December 30, 2025. The new facility adds a significant production capacity of 0.45 Million Tonnes Per Annum (MTPA), which is expected to bolster the company's overall steel output. The plant is designed with zero process water discharge, emphasizing sustainability and operational efficiency. This expansion aligns with the company's long-term growth strategy to strengthen its market presence in the steel sector.
Key Highlights
Commissioned a Modern Blast Furnace and Linear Sinter Plant at step-down subsidiary Ramsarup Industries Limited
Added 0.45 Million Tonnes Per Annum (MTPA) of production capacity to the group's portfolio
Commercial production officially started on December 30, 2025
Plant features a zero process water discharge design to promote sustainability and process efficiency
💼 Action for Investors
Investors should view this capacity addition as a positive catalyst for revenue growth in the coming quarters. Monitor the utilization levels of the new plant and its impact on the company's consolidated margins.
Vineet Laboratories to Raise ₹29.97 Crore via Rights Issue at ₹30 Per Share
Vineet Laboratories Limited has submitted its Letter of Offer for a Rights Issue aiming to raise approximately ₹29.97 crore. The company will issue 99,87,258 equity shares at a price of ₹30 per share, which includes a premium of ₹20. The rights entitlement ratio is fixed at 13 shares for every 12 shares held by eligible shareholders as of the record date, December 23, 2025. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
Key Highlights
Rights issue size of up to 99,87,258 shares aggregating to ₹29.97 Crores
Issue price set at ₹30 per share (Face Value ₹10 + Premium ₹20)
Rights entitlement ratio of 13:12 for shareholders as of December 23, 2025
Subscription period opens on January 01, 2026, and closes on January 21, 2026
On-market renunciation period ends on January 16, 2026
💼 Action for Investors
Existing shareholders should monitor the market price relative to the ₹30 offer price and decide whether to subscribe, renounce, or sell their rights entitlements before the January 16 deadline.
Vineet Laboratories Receives BSE and NSE Approval for Rs 30 Crore Rights Issue
Vineet Laboratories Limited has secured in-principle approvals from both the National Stock Exchange (NSE) and BSE Limited to undertake a Rights Issue of fully paid-up equity shares. The company plans to raise up to Rs 30 Crores through this issue, offering shares with a face value of Rs 10 each. A board meeting is scheduled for December 17, 2025, to finalize the issue price, entitlement ratio, and record date. This capital infusion is expected to strengthen the company's balance sheet, though it will result in equity dilution for existing shareholders who do not participate.
Key Highlights
Received in-principle approval from NSE on December 02, 2025, and BSE on December 16, 2025.
The proposed Rights Issue aims to aggregate up to a total of Rs 30 Crores.
Board meeting scheduled for December 17, 2025, to determine the issue price, entitlement ratio, and record date.
The issue involves fully paid-up equity shares with a face value of Rs 10 each.
💼 Action for Investors
Existing shareholders should wait for the announcement of the issue price and entitlement ratio to assess the discount offered compared to the market price. Investors should decide whether to subscribe to avoid dilution or sell their rights entitlements if the company allows renunciation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 17 for Price Finalization
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting from December 16 to December 17, 2025. The committee is scheduled to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the proposed capital raise. This delay is intended to facilitate the receipt of in-principle approval from BSE Limited. Investors should monitor the upcoming announcement as it will define the terms of equity dilution and the cost of new shares.
Key Highlights
Rights Issue Committee meeting adjourned from December 16 to December 17, 2025.
Committee to determine key modalities: Issue Price, Entitlement Ratio, and Record Date.
Finalization is subject to receiving in-principle approval from BSE Limited.
The initial meeting on December 16 lasted only 30 minutes (6:20 P.M. to 6:50 P.M.) before adjournment.
💼 Action for Investors
Wait for the finalized terms on December 17 to evaluate the attractiveness of the rights issue price compared to the current market price. Assess the potential dilution effect once the entitlement ratio is announced.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 16, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 15, 2025, to December 16, 2025. The committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the upcoming rights issue. This adjournment is intended to allow time for the receipt of in-principle approval from the BSE. The meeting on December 15 lasted only 20 minutes before the decision to adjourn was made.
Key Highlights
Rights Issue Committee meeting adjourned from December 15 to December 16, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date
Adjournment pending in-principle approval from BSE Ltd
The initial meeting on December 15 commenced at 7:00 PM and was adjourned at 7:20 PM
💼 Action for Investors
Investors should wait for the adjourned meeting's outcome on December 16 to understand the pricing and dilution impact of the rights issue. Compare the announced issue price with the current market price to determine the attractiveness of the offer.
Standard Glass Lining Tech Renamed to Standard Engineering Technology; Broadens Business Scope
Standard Glass Lining Technology Limited has officially changed its name to Standard Engineering Technology Limited following shareholder approval on December 14, 2025. This rebranding reflects the company's evolution from a specialized glass-lined equipment manufacturer to a provider of advanced engineering and turnkey project solutions. The company has also significantly expanded its Memorandum of Association (MOA) to include high-growth sectors such as nuclear, hydrogen, solar, and semiconductors. These amendments align the corporate identity with its diversified business profile and global expansion goals.
Key Highlights
Company name changed to Standard Engineering Technology Limited to reflect a broader engineering profile.
Main Objects clause expanded to include high-precision fabrication, EPC models, and turnkey project solutions.
Target industries now explicitly include nuclear, hydrogen, solar, semiconductor, and defense sectors.
Special Resolutions were passed by shareholders via Postal Ballot with the requisite majority on December 14, 2025.
The amendment includes new sub-clauses for technology transfer, R&D, and global strategic alliances.
💼 Action for Investors
Investors should view this as a strategic move to transition into higher-value engineering and clean energy markets. Monitor the company's order book for new contracts in the newly added high-tech sectors like nuclear and semiconductors.
Standard Glass Lining Tech Shareholders Approve ESOP 2024 and Company Name Change
Shareholders of Standard Glass Lining Technology Limited have approved six special resolutions via postal ballot, including the ratification and amendment of the 'Employee Stock Option Plan 2024'. The resolutions also extend ESOP benefits to employees of subsidiary and associate companies to align interests across the group. Additionally, the company received overwhelming support for a name change and an amendment to its objects clause in the Memorandum of Association. All resolutions passed with over 99% of votes in favor, reflecting strong shareholder confidence in management's strategic initiatives.
Key Highlights
Ratification and amendment of 'Employee Stock Option Plan 2024' passed with 100% and 99.99% favor respectively.
Extension of ESOPs to employees of subsidiary and associate companies approved with 100% and 99.45% support.
Resolution for changing the company name and amending the Memorandum of Association passed with nearly 100% support.
A total of 155,883,808 votes were polled, representing 78.14% of the total outstanding shares of the company.
The voting process involved 258 members exercising their votes through remote e-voting between Nov 15 and Dec 14, 2025.
💼 Action for Investors
Investors should monitor the official announcement of the new company name and any subsequent shifts in business focus following the amendment of the objects clause. The broad approval for ESOPs indicates a management focus on long-term talent retention and alignment.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 12, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 11, 2025, to December 12, 2025. The committee is expected to finalize critical terms of the proposed fundraising, including the Issue Price, Entitlement Ratio, and Record Date. This delay is reportedly to facilitate the receipt of in-principle approval from BSE Ltd. The initial meeting on December 11 lasted only 20 minutes before the adjournment was called.
Key Highlights
Rights Issue Committee meeting adjourned from December 11 to December 12, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date for the proposed Rights Issue
Finalization is subject to receiving in-principle approval from BSE Ltd
The meeting on December 11 commenced at 6:00 PM and was adjourned by 6:20 PM
💼 Action for Investors
Investors should wait for the adjourned meeting's outcome on December 12 to evaluate the rights issue price and potential equity dilution.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 11, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, which was originally scheduled for December 9, 2025. The meeting is now set to reconvene on Thursday, December 11, 2025, to finalize the terms of the proposed fundraising. The committee is expected to determine the Issue Price, Entitlement Ratio, and Record Date during this session. This adjournment is necessary to await the in-principle approval from the BSE Limited.
Key Highlights
Rights Issue Committee meeting adjourned from December 9 to December 11, 2025
Meeting will finalize critical details including Issue Price and Entitlement Ratio
Adjournment is pending the receipt of in-principle approval from BSE Ltd
The initial meeting on December 9 lasted only 20 minutes before adjournment
💼 Action for Investors
Investors should monitor the upcoming announcement on December 11 for specific rights issue terms. Evaluate the issue price relative to the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 9, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 6, 2025. The meeting is now rescheduled for Tuesday, December 9, 2025, as the company awaits in-principle approval from BSE Limited. During the upcoming session, the committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date. This fundraise is a significant event for the company's capital structure and liquidity.
Key Highlights
Rights Issue Committee meeting adjourned from December 6 to December 9, 2025
Committee to decide on Issue Price, Entitlement Ratio, and Record Date
Adjournment necessitated by pending In-principle approval from BSE Ltd
The initial meeting on Dec 6 lasted only 30 minutes before being adjourned
💼 Action for Investors
Investors should monitor the announcement on December 9 for the rights issue price and ratio to assess potential dilution and investment value.
Vineet Laboratories Rights Issue Committee Meeting Adjourned to Dec 6
Vineet Laboratories has adjourned its Rights Issue Committee meeting, which commenced on December 3, 2025, at 3:00 P.M., to December 6, 2025. The adjournment is to allow the committee to further consider the Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates, and other modalities of the proposed Rights Issue. This is pending receipt of in-principle approval from BSE Ltd. The initial meeting on December 3rd lasted from 3:00 P.M. to 4:00 P.M.
Key Highlights
Rights Issue Committee meeting adjourned to December 6, 2025
Initial meeting commenced on December 3, 2025, at 3.00 P.M.
Initial meeting adjourned at 4.00 P.M.
Considering Issue Price, Entitlement Ratio, Record date, Issue opening and closing dates
💼 Action for Investors
Investors should monitor for the announcement of the Issue Price, Entitlement Ratio, Record date, and Issue dates on December 6, 2025. Evaluate the terms of the rights issue to determine whether to participate.